Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P516: Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trialsECCO '18 Vienna
Year: 2018
Authors:

J. Panés1*, B. Bressler2, J.-F. Colombel3, N. Lawendy4, E. Maller4, H. Zhang4, D.A. Woodworth4, G. Chan4, L. Salese4, C. Su4

1Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2University of British Columbia, Division of Gastroenterology, Department of Medicine, Vancouver, BC, Canada, 3Icahn School of Medicine at Mount Sinai Hospital, Division of Gastroenterology, New York, NY, USA, 4Pfizer Inc., Collegeville, PA, USA

P517: The effects and adherence of Asacol® comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: Prospective multicentre randomised studyECCO '18 Vienna
Year: 2018
Authors:

S.-K. Park1*, C.S. Eun2, G.S. Seo3, J. Lim4, T.O. Kim5, D.I. Park1

1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Internal Medicine, Seoul, South Korea, 2Hanyang University Guri Hospital, Guri, South Korea, 3Wonkwang University, Department of Internal Medicine, Jeonbuk, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Haeundae Paik Hospital, Inje University College of Medicine, Department of Internal Medicine and Gastroenterology, Busan, South Korea

P518: Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

C.-Y. Chao1,2*, S. Restellini1,3, C. Lemieux1, P. Germain1, A. Bitton1, P.L. Lakatos1,4, G. Wild1, E. Seidman1, T. Bessissow1, W. Afif1

1McGill University Health Centre, Division of Gastroenterology, Montréal, Canada, 2Princess Alexandra Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia, 3Geneva University Hospitals and University of Geneva, Department of Gastroenterology and Hepatology, Geneva, Switzerland, 4Semmelweis University, Department of Gastroenterology, Budapest, Hungary

P519: Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months resultsECCO '18 Vienna
Year: 2018
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, J.M. Vázquez Morón2, H. Pallarés Manrique2, T. Valdes Delgado1, L. Castro Laria1, B. Maldonado Pérez1, R. Perea Amarillo1, V. Merino3, A. Caunedo Álvarez1, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Sevilla, Spain, 2Juan Ramón Jiménez Hospital, Gastroenterology, Huelva, Spain, 3Virgen Macarena Hospital, Pharmacy Unit, Sevilla, Spain

P520: Gastrointestinal ultrasonography in pregnant patients with IBD is useful in the identification of active intestinal inflammationECCO '18 Vienna
Year: 2018
Authors:

E. Flanagan1, E. Wright1, J. Begun2,3, R. Bryant4,5, D. Sathananthan4, S. Bell1*

1St Vincent's Hospital, Gastroenterology, Melbourne, Australia, 2Mater Hospital, Gastroenterology, Brisbane, Australia, 3Mater Research Institute, Brisbane, Australia, 4Queen Elizabeth Hospital, Gastroenterology, Adelaide, Australia, 5University of Adelaide, Adelaide, Australia

P521: Evaluation of adalimumab effectiveness in paediatric patients with ulcerative colitis in clinical practiceECCO '18 Vienna
Year: 2018
Authors:

S. Steiner1*, C. Liu2, E. King2, E. Israel3, B. Pasternak4, M. Schaefer5, S. Chen2, J. Pratt2, A. Lazar6, M. Bereswill6, A. Robinson7, R. Colletti8, ImproveCareNow Network9

1Indiana University School of Medicine, Indianapolis, USA, 2Cincinnati Children's Hospital Medical Center, Cincinnati, USA, 3Massachusetts General Hospital for Children, Boston, USA, 4Phoenix Children's Hospital, Phoenix, USA, 5Penn State Children's Hospital, Hershey, USA, 6Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 7AbbVie, North Chicago, USA, 8University of Vermont Children’s Hospital, Burlington, USA, 9ImproveCareNow, Burlington, USA

P522: Soluble sMadCAM1 and retinoic acid are potential tools for therapeutic drug monitoring in inflammatory bowel disease s under vedolizumab: A proof of conceptECCO '18 Vienna
Year: 2018
Authors:

X. Roblin1*, N. Williet1, G. Boschetti2, B. Flourie2, E. Del Tedesco3, L. Peyrin Biroulet4, J.m. Phelip3, S. Nancey2, S. Paul5

1CHU Saint Etienne, Saint Etienne, France, 2University of Lyon, Lyon, France, 3University Hospital, Gastroenterology, Saint Etienne, France, 4CHU de Nancy, Department of Gastroenterology, Vandoeuvre-les-Nancy, France, 5University of Saint Etienne, Immunology, Saint Etienne, France

P523: New guidance on therapeutic drug monitoring; potential clinical and cost implicationECCO '18 Vienna
Year: 2018
Authors:

R. Felwick*, H. Johnson, H. Dewhurst, E. Cadogan, C. Hovell, S. Weaver, S. McLaughlin

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, UK

P524: Active smoking and personal concerns about treatment can impair adherence to adalimumab in inflammatory bowel diseases: A prospective evaluationECCO '18 Vienna
Year: 2018
Authors:

I. Bruna-Barranco1, P. Alarcon2, A. Lué3,4, C. Gargallo3,4, E. Alfambra4, M. Gimeno5, F. Gomollon2,3,4,6*

1Hospital Universitario Miguel Servet, Zaragoza, Spain, 2Universidad de Zaragoza, Zaragoza, Spain, 3Fundación IIS Aragon, Zaragoza, Spain, 4Hospital Clinico Universitario Lozano Blesa, Gastroenterology Department, Zaragoza, Spain, 5Hospital Clinico Universitario Lozano Blesa, Pharmacy Department, Zaragoza, Spain, 6CIBERehd, Barcelona, Spain

P525: Adherence and persistence with vedolizumab among patients with inflammatory bowel disease in an academic medical centreECCO '18 Vienna
Year: 2018
Authors:

K. Null1*, H.L. Chang2, T. Lissoos1, M. Luo1, B. Cohen2, B.E. Sands2, A. Atreja2

1Takeda Pharmaceuticals USA, Inc., Deerfield, USA, 2Icahn School of Medicine at Mount Sinai, New York, USA

P526: Early sonographic response predicts long-term outcome in Crohn’s disease: A prospective cohort studyECCO '18 Vienna
Year: 2018
Authors:

K. Novak1*, J. Halasz1, C. Lu1, G. Kaplan1,2, C. Seow1, D. Tanyingoh2, S. Devlin1, R. Panaccione1, S. Wilson3

1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Community Health Sciences, Calgary, Canada, 3University of Calgary, Foothills Medical Centre, Diagnostic Imaging, Calgary, Canada

P527: Low adalimumab serum levels at Week 4 provoke immunogenicity and influence therapy outcome in anti-TNF naïve Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

B. Verstockt1,2*, G. Moors1, S. Bian3, T. Van Stappen3, S. Tops3, V. Ballet1, G. Van Assche1,2, S. Vermeire1,2, A. Gils3, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P528: Patients’ perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort studyECCO '18 Vienna
Year: 2018
Authors:

N. Petitdidier1*, C. Gagniere1, A.L. Rentien1, J. Tannoury1, Y. Le Baleur2, F. Mesli1, I. Sobhani1, A. Amiot1

1Hopital Henri Mondor, Gastroenterology, Créteil, France, 2Hopital Saint Joseph, Gastroenterology, Paris, France

P529: Longer duration of vancomycin prevents recurrence of C. difficile in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

D. Lei*, M.J. Andersen Jr., R. Weisshof, N. Meter, D.T. Rubin

University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, USA

P530: Psychosexual dysfunction in Greek patients with inflammatory bowel disease in remissionECCO '18 Vienna
Year: 2018
Authors:

N. Dimitriadis, D. Xanthis, P. Paschos, A. Katsoula, N. Grammatikos, A. Tsimperidis, K. Soufleris, O. Giouleme*

Aristotle University, Hippokration Hospital, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece

P531: Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agentsECCO '18 Vienna
Year: 2018
Authors:

M. Fragaki*, G. Paspatis, K. Karmiris

Venizelion General Hospital, Department of Gastroenterology, Heraklion, Greece

P532: Efficacy of combination therapy with cyclosporin and vedolizumab in inflammatory bowel diseases refractory to anti-TNF agentsECCO '18 Vienna
Year: 2018
Authors:

M. Rutka*, K. Szántó, R. Bor, A. Bálint, A. Fábián, A. Milassin, Z. Szepes, K. Farkas, T. Molnar

University of Szeged, 1st Department of Medicine, Szeged, Hungary

P533: Correlation of endoscopic and clinical endpoints during induction therapy in patients with moderate-to-severe Crohn’s disease: Analysis from CELEST studyECCO '18 Vienna
Year: 2018
Authors:

W.J. Sandborn1*, B. Feagan2, J.D. Lewis3, S. Danese4, W. Reinisch5, D.T. Rubin6, W. Zhou7, F. Cataldi7, Q. Zhou7, S. Goteti7, A.P. Lacerda7

1University of California San Diego, La Jolla, USA, 2Robarts Clinical Trials, London, Canada, 3Perelman School of Medicine at The University of Pennsylvania, Philadelphia, USA, 4Istituto Clinico Humanitas, Milan, Italy, 5Medical University of Vienna, Vienna, Austria, 6University of Chicago Medicine, Chicago, USA, 7AbbVie Inc., North Chicago, USA

P534: Spontaneous intra-abdominal abscess in Crohn's disease: Efficacy of non-surgical management and prognostic factorsECCO '18 Vienna
Year: 2018
Authors:

A. Labidi1*, S. Hamdi1, M. Ben Abbes1, N. Ben Mustapha1, M. Hafi1, H. Maghrebi2, M. Fekih1, L. Zouiten1, M. Serghini1, J. Boubaker1

1Rabta Hospital, Gastroenterology “A”, Tunis, Tunisia, 2Rabta Hospital, Surgery “A”, Tunis, Tunisia

P535: The use of therapeutic drug monitoring for infliximab and adalimumab in inflammatory bowel disease: Practice patterns, understanding and interpretationECCO '18 Vienna
Year: 2018
Authors:

M.A. Samaan*, P.M. Irving

Guy's and St Thomas' Hospital, Gastroenterology, London, UK